Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.
Debu Tripathy, MD, professor, and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role margetuximab (Margenza) will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.
Tripathy says that the design of the agent is very interesting as it was created to augment and better interact with the immune system. This is a concept that has been thought of for a long time because the immune system plays an important role in how patients with HER2-positive breast cancer respond to therapy.
In preclinical models, margetuximab stood out from other IgG antibodies because it is engineered for the Fc portion of the antibody. Clinically, margetuximab was tested in humans in the phase in the phase 3 SOPHIA clinical trial (NCT02492711). The study showed did show that margetuximab is making a difference in patients with HER2-positive metastatic breast cancer, Tripathy states. But the level of efficacy observed with the agent in SOPHIA warrant further follow-up.
Overall, Tripathy believes that margetuximab will serve a good purpose for patients withHER2-positive metastatic breast cancer in later-line settings.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
Study Reveals Encouraging Results in HER2+ Breast Cancer With Brain Mets
November 1st 2024Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Read More